- Home
- HRZN vs GALT Comparison
HRZN vs GALT Comparison
Compare HRZN & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HRZN | GALT |
|---|---|---|
| Founded | 2008 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 322.2M | 297.0M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | HRZN | GALT |
|---|---|---|
| Price | $4.67 | $3.39 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $6.50 | ★ $8.50 |
| AVG Volume (30 Days) | ★ 572.5K | 528.1K |
| Earning Date | 05-05-2026 | 05-15-2026 |
| Dividend Yield | ★ 33.85% | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.25 | N/A |
| Revenue Next Year | $22.53 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.80 | $2.03 |
| 52 Week High | $7.28 | $7.13 |
Technical Indicators
Market Signals| Indicator | HRZN | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 55.00 | 43.95 |
| Support Level | $4.56 | $2.75 |
| Resistance Level | $4.76 | $3.35 |
| Average True Range (ATR) | 0.16 | 0.32 |
| MACD | 0.00 | -0.11 |
| Stochastic Oscillator | 79.61 | 28.78 |
Price Performance
Historical ComparisonAbout HRZN Horizon Technology Finance Corporation
Horizon Technology Finance Corp is a specialty finance company. Its investment objective is to maximize its investment portfolio's total return by generating current income from the debt investments it makes and capital appreciation from the warrants it receives when making such debt investments. It lends to and invests in development-stage companies in the technology, life science, healthcare information and services, and sustainability industries.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.